SKL PSY
Alternative Names: FZ-016; SKL-PSY/FZ-016Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator SK biopharmaceuticals
- Developer Shanghai Medicilon; SK biopharmaceuticals
- Class Antidepressants; Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bipolar disorders
- Discontinued Anxiety disorders; Depressive disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Bipolar-disorders in USA
- 22 Feb 2022 SKL PSY is still in phase I trial for Bipolar Disorder in USA (SK Biopharmaceuticals pipeline, February 2022)
- 22 Feb 2022 Discontinued - Preclinical for Anxiety disorders in South Korea (unspecified route) (SK biopharmaceuticals pipeline, February 2022)